Language: BG BG
← Back to results
Recruiting Phase 2 NCT07451171

Comparative Efficacy of Antibiotics for Small Intestine Bacterial Overgrowth in Bangladeshi Children

Phase 2 – studying effectiveness and dosage
Conditions: Small Intestine Bacterial Overgrowth

Sponsor: University of Virginia

trial.available_in: БГ
Overview
The purpose of this Phase IIa study is to identify the most effective antibiotic regimen to treat small intestine bacterial overgrowth (SIBO) in impoverished Bangladeshi children.
Who can participate
Inclusion Criteria: * Positive glucose hydrogen breath test (GHBT) * Weight-for-age Z score \> -1 * Length-for-age Z score \> -1 Exclusion Criteria: * Presence of known chronic or congenital illness, including developmental delay * Presence of acute gastrointestinal illness in the preceding 14 days * Antibiotic use in the preceding 14 days * Previous adverse reaction to any of the three study medications or other drugs in the same antibiotic classes * Sibling previously enrolled in this study
Interventions
Trimethoprim-sulfamethoxazole (TMP/SMX)
DRUG
Metronidazole
DRUG
Amoxicillin-Clavulanate (4:1 formulation)
DRUG
Locations 1
Bangladesh (1)
International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b)
Dhaka
Rashidul Haque, MBBS, PhD
Technical details
Status
Recruiting
Phase
Phase 2
Study type
INTERVENTIONAL
Sex
Male and female
Minimum age
1 Year
Maximum age
2 Years
Healthy volunteers
No
Start date
15.04.2026
Completion date
01.06.2026
Registry ID
NCT07451171
Source
clinicaltrials.gov
trial.inquiry_btn

Information is automatically extracted from ClinicalTrials.gov. Consult your doctor before taking action.